SCHEMBL661922

SCHEMBL661922

BrN1C=NC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5888235 0.71
SCHEMBL580953 0.67
SCHEMBL6427950 0.67
SCHEMBL8508693 0.67
SCHEMBL17157487 0.67
SCHEMBL3628674 0.67
SCHEMBL1431147 0.67
SCHEMBL27639 0.62
SCHEMBL8506228 0.62
SCHEMBL2146911 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808118-A Phosphorescent material, manufacturing method thereof and OLED device 上海和辉光电有限公司 2020-10-23 CN claimed
EP-3820859-B1 INHIBITORS OF HISTONE DEACETYLASE ALKERMES INC (US) 2024-03-20 EP disclosed
US-20210276978-A1 INHIBITORS OF HISTONE DEACETYLASE ALKERMES, INC. 2021-09-09 US disclosed
EP-3820859-A1 INHIBITORS OF HISTONE DEACETYLASE Alkermes, Inc. (US) 2021-05-19 EP disclosed
CN-112424184-A Bicyclic inhibitors of histone deacetylase 奥克梅斯公司 2021-02-26 CN disclosed
CN-111808118-A Phosphorescent material, manufacturing method thereof and OLED device 上海和辉光电有限公司 2020-10-23 CN disclosed
US-10550140-B2 Ether compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2020-02-04 US disclosed
US-10385097-B2 Ether compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2019-08-20 US disclosed
US-20190048033-A1 ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2019-02-14 US disclosed
US-10106563-B2 Ether compounds for treatment of complement mediated disorders Achillion Pharmaecuticals, Inc. (US) 2018-10-23 US disclosed
US-7652051-B2 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2010-01-26 US disclosed
US-20090306121-A1 AZA-BETA-CARBOLINES AND METHODS OF USING SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2009-12-10 US disclosed
WO-2009143445-A1 AZA-BETA-CARBOLINES AND METHODS OF USING SAME THE UWM RESEARCH FOUNDATION, INC (US) 2009-11-26 WO disclosed
EP-1799656-A4 HETEROCYCLIC COMPOUNDS AND METHODS OF USE TARGEGEN INC (US) 2009-09-02 EP disclosed
EP-1799656-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Targegen, Inc. (US) 2007-06-27 EP disclosed
US-20060079526-A1 Heterocyclic compounds and methods of use TARGEGEN, INC. (US) 2006-04-13 US disclosed
WO-2006024034-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE TARGEGEN, INC. (US) 2006-03-02 WO disclosed
EP-0148826-A1 FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1985-07-24 EP disclosed
WO-1985000289-A1 FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS CHEVRON RESEARCH COMPANY (US) 1985-01-31 WO disclosed
EP-0037591-A1 Phenoxy-pyrimidinyl alkanols, process for their preparation and their use as fungicides BAYER AG (DE) 1981-10-14 EP disclosed